Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Dyslexia

Rockwood Clinic is conducting a research study to assess the effectiveness of atomoxetine, an approved medication in an investigational use, versus placebo (an inactive, look-alike pill) in reducing symptoms in children or adolescents with attention-deficit/hyperactivity disorder (ADHD) and/or dyslexia.

 

Your child may qualify for this study if they:

  • Are at least 10 years old and no more than 16 years old
  • Meet criteria for a diagnosis of ADHD and/or dyslexia
  • Are able to swallow capsules
  • Are willing to use a reliable method of birth control during the study

 

Qualified participants will receive the following at no charge:

  • Study-related physical exams, labs, and ADHD testing
  • Study medications
  • Travel compensation

 

If you are interested in learning more about this study or to find out if your child may qualify, please contact Jaime -at (509) 755-6882.

 

Principal Investigator
Stephen Luber, M.D. (refer to CT1L study)